Teva Pharmaceutical Industries Limited Company Profile (NYSE:TEVA)

About Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Teva Pharmaceutical Industries Limited logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:TEVA
  • CUSIP: N/A
  • Web: www.tevapharm.com
Capitalization:
  • Market Cap: $17.46504 billion
  • Outstanding Shares: 1,016,000,000
Average Prices:
  • 50 Day Moving Avg: $18.13
  • 200 Day Moving Avg: $28.20
  • 52 Week Range: $15.22 - $51.51
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 4.39
  • P/E Growth: -0.82
Sales & Book Value:
  • Annual Revenue: $23.37 billion
  • Price / Sales: 0.75
  • Book Value: $23.99 per share
  • Price / Book: 0.72
Dividend:
  • Annual Dividend: $0.94
  • Dividend Yield: 5.5%
Profitability:
  • EBIDTA: $7.42 billion
  • Net Margins: -25.18%
  • Return on Equity: 15.96%
  • Return on Assets: 5.31%
Debt:
  • Debt-to-Equity Ratio: 1.30%
  • Current Ratio: 0.94%
  • Quick Ratio: 0.61%
Misc:
  • Average Volume: 20.06 million shs.
  • Beta: 0.57
  • Short Ratio: 4.71
 

Frequently Asked Questions for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

What is Teva Pharmaceutical Industries Limited's stock symbol?

Teva Pharmaceutical Industries Limited trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries Limited pay dividends? What is the dividend yield for Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited declared a quarterly dividend on Monday, August 7th. Investors of record on Tuesday, August 29th will be given a dividend of $0.085 per share on Thursday, September 14th. This represents a $0.34 annualized dividend and a dividend yield of 1.98%. The ex-dividend date is Friday, August 25th. View Teva Pharmaceutical Industries Limited's Dividend History.

How were Teva Pharmaceutical Industries Limited's earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued its earnings results on Thursday, August, 3rd. The company reported $0.99 earnings per share for the quarter, missing the consensus estimate of $1.06 by $0.07. The business had revenue of $5.69 billion for the quarter, compared to analysts' expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. Teva Pharmaceutical Industries Limited's revenue for the quarter was up 12.9% on a year-over-year basis. During the same period in the prior year, the firm posted $1.25 EPS. View Teva Pharmaceutical Industries Limited's Earnings History.

When will Teva Pharmaceutical Industries Limited make its next earnings announcement?

Teva Pharmaceutical Industries Limited is scheduled to release their next quarterly earnings announcement on Tuesday, November, 21st 2017. View Earnings Estimates for Teva Pharmaceutical Industries Limited.

What guidance has Teva Pharmaceutical Industries Limited issued on next quarter's earnings?

Teva Pharmaceutical Industries Limited updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided earnings per share (EPS) guidance of $4.30-4.50 for the period, compared to the Thomson Reuters consensus estimate of $4.73. The company issued revenue guidance of $22.8-23.2 billion, compared to the consensus revenue estimate of $23.43 billion.

Where is Teva Pharmaceutical Industries Limited's stock going? Where will Teva Pharmaceutical Industries Limited's stock price be in 2017?

27 brokerages have issued 12 month price targets for Teva Pharmaceutical Industries Limited's shares. Their predictions range from $13.00 to $80.00. On average, they anticipate Teva Pharmaceutical Industries Limited's share price to reach $31.24 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries Limited.

What are analysts saying about Teva Pharmaceutical Industries Limited stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries Limited stock:

  • 1. According to Zacks Investment Research, "Teva missed estimates for both earnings and sales in Q2. The company also slashed its 2017 earnings and sales outlook to reflect the challenging environment in the U.S. generics business and the continued deterioration in Venezuela. Teva also announced a 75% cut in its dividend. The U.S. generics industry’s competitive and pricing pressure is expected to continue in the near future. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products, a high cost base and debt load and the sudden departure of its CEO. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to the growth of the Generics unit. However, a clear path to growth is not visible." (8/9/2017)
  • 2. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)
  • 3. Maxim Group analysts commented, "We reviewed and revised our model prior to the 1Q17 earnings release. Based on 2017 guidance and our expectations, we adjust OTC revenues in 1Q17 to $277M from $346M to reflect the change in foreign exchange rate as of December 1, 2016. Our estimate for total 2017 revenues is unchanged at $24B." (3/29/2017)
  • 4. Royal Bank Of Canada analysts commented, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures." (2/14/2017)

Are investors shorting Teva Pharmaceutical Industries Limited?

Teva Pharmaceutical Industries Limited saw a increase in short interest in August. As of August 31st, there was short interest totalling 45,757,204 shares, an increase of 9.1% from the August 15th total of 41,926,083 shares. Based on an average daily trading volume, of 17,819,656 shares, the short-interest ratio is currently 2.6 days.

Who are some of Teva Pharmaceutical Industries Limited's key competitors?

Who are Teva Pharmaceutical Industries Limited's key executives?

Teva Pharmaceutical Industries Limited's management team includes the folowing people:

  • Sol J. Barer, Chairman of the Board
  • Yitzhak Peterburg, Interim President and Chief Executive Officer
  • Kaare Schultz, President, Chief Executive Officer
  • Eyal Desheh, Group Executive Vice President, Chief Financial Officer
  • Dipankar Bhattacharjee, President and Chief Executive Officer-Global Generic Medicines Group
  • Carlo de Notaristefani, President and Chief Executive Officer-Global Operations
  • Robert Koremans, President, Chief Executive Officer - Global Specialty Medicines
  • Iris Beck-Codner, Group Executive Vice President - Corporate Marketing & Communication
  • Hafrun Fridriksdottir, Executive Vice President, President of Global Generics R&D
  • Mark Sabag, Group Executive Vice President-Human Resources

Who owns Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (7.51%), Franklin Resources Inc. (6.57%), FMR LLC (4.22%), Bank of New York Mellon Corp (1.79%), Northern Cross LLC (1.75%) and Nordea Investment Management AB (1.27%). View Institutional Ownership Trends for Teva Pharmaceutical Industries Limited.

Who sold Teva Pharmaceutical Industries Limited stock? Who is selling Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was sold by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Bank of New York Mellon Corp, FIL Ltd, Janus Henderson Group PLC, South Texas Money Management Ltd., Great West Life Assurance Co. Can, Banque Pictet & Cie SA and Commerzbank Aktiengesellschaft FI. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

Who bought Teva Pharmaceutical Industries Limited stock? Who is buying Teva Pharmaceutical Industries Limited stock?

Teva Pharmaceutical Industries Limited's stock was purchased by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Franklin Resources Inc., FMR LLC, Capital World Investors, Alliancebernstein L.P., Migdal Insurance & Financial Holdings Ltd., Northern Cross LLC and Polaris Capital Management LLC. View Insider Buying and Selling for Teva Pharmaceutical Industries Limited.

How do I buy Teva Pharmaceutical Industries Limited stock?

Shares of Teva Pharmaceutical Industries Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries Limited's stock price today?

One share of Teva Pharmaceutical Industries Limited stock can currently be purchased for approximately $17.19.


MarketBeat Community Rating for Teva Pharmaceutical Industries Limited (NYSE TEVA)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  866 (Vote Outperform)
Underperform Votes:  655 (Vote Underperform)
Total Votes:  1,521
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries Limited and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Teva Pharmaceutical Industries Limited (NYSE:TEVA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 17 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.15)
Consensus Price Target: $31.24 (81.71% upside)

Analysts' Ratings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/21/2017Sanford C. BernsteinLower Price TargetMkt Perform -> Market Perform$28.00 -> $20.00LowView Rating Details
9/18/2017Cantor FitzgeraldReiterated RatingHold$17.00LowView Rating Details
9/18/2017Royal Bank Of CanadaLower Price TargetUnderperform$21.00 -> $15.00HighView Rating Details
9/14/2017Maxim GroupReiterated RatingHold$15.50LowView Rating Details
9/13/2017GabelliReiterated RatingBuyLowView Rating Details
9/11/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldLowView Rating Details
9/12/2017Jefferies Group LLCLower Price TargetHold$21.00 -> $18.50HighView Rating Details
9/11/2017BTIG ResearchUpgradeNeutral -> Buy$24.00HighView Rating Details
9/6/2017JMP SecuritiesBoost Price TargetUnderperform$13.00 -> $14.00LowView Rating Details
8/31/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$28.00 -> $21.00LowView Rating Details
8/23/2017Credit Suisse GroupDowngradeNeutral -> Underperform$25.00 -> $13.00MediumView Rating Details
8/22/2017MizuhoReiterated RatingNeutral$30.00 -> $16.00LowView Rating Details
8/16/2017Citigroup Inc.DowngradeBuy -> Neutral$32.00 -> $19.00MediumView Rating Details
8/9/2017Deutsche Bank AGReiterated RatingBuy$43.00 -> $28.00HighView Rating Details
8/7/2017Barclays PLCLower Price TargetEqual Weight$38.00 -> $23.00HighView Rating Details
8/4/2017Piper Jaffray CompaniesReiterated RatingNeutral$28.00 -> $23.00HighView Rating Details
8/4/2017Cowen and CompanyDowngradeOutperform -> Market Perform$50.00 -> $30.00HighView Rating Details
8/3/2017CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
6/27/2017Wells Fargo & CompanyReiterated RatingHoldN/AView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
2/17/2017J P Morgan Chase & CoSet Price TargetHold$37.00N/AView Rating Details
1/31/2017Bank of America CorporationUpgradeNeutral -> BuyN/AView Rating Details
12/23/2016GuggenheimReiterated RatingBuy$80.00N/AView Rating Details
12/4/2016Morgan StanleyDowngradeOverweight -> Equal Weight$63.00 -> $42.00N/AView Rating Details
11/4/2016HSBC Holdings plcDowngradeBuy -> Hold$44.00 -> $66.00N/AView Rating Details
10/7/2016Leerink SwannSet Price TargetBuy$57.00N/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00N/AView Rating Details
11/27/2015Berenberg BankLower Price TargetHold$72.00 -> $65.00N/AView Rating Details
(Data available from 9/25/2015 forward)

Earnings

Earnings History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Earnings by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Earnings History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/21/2017        
8/3/20176/30/2017$1.06$0.99$5.72 billion$5.69 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.69 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Current Year EPS Consensus Estimate: $4.19 EPS
Next Year EPS Consensus Estimate: $3.92 EPS

Dividends

Current Dividend Information for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Most Recent Dividend:9/14/2017
Annual Dividend:$0.94
Dividend Yield:5.47%
Dividend Growth:2.10% (3 Year Average)
Payout Ratio:-15.36% (Trailing 12 Months of Earnings)
22.43% (Based on This Year's Estimates)
23.98% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Dividend History by Quarter for Teva Pharmaceutical Industries Limited (NYSE TEVA)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/7/2017quarterly$0.091.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Latest Headlines for Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Source:
DateHeadline
prnewswire.com logoTEVA PHARMACEUTICAL SHAREHOLDER ALERT: CLAIMSFILER ... - PR Newswire (press release)
www.prnewswire.com - September 23 at 3:23 PM
americanbankingnews.com logo Analysts Expect Teva Pharmaceutical Industries Limited (TEVA) Will Announce Quarterly Sales of $5.63 Billion
www.americanbankingnews.com - September 23 at 2:00 PM
businesswire.com logoGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the ...
www.businesswire.com - September 23 at 9:58 AM
finance.yahoo.com logo[$$] Teva Pharmaceutical Stock Could Double
finance.yahoo.com - September 23 at 9:58 AM
finance.yahoo.com logoScott+Scott, Attorneys at Law, LLP Reminds Investors of October 23rd Lead Plaintiff Deadline in Class Action Against Teva Pharmaceutical Industries Ltd. (TEVA)
finance.yahoo.com - September 23 at 9:58 AM
finance.yahoo.com logoGlancy Prongay & Murray Announces the Filing of a Securities Class Action on Behalf of Teva Pharmaceutical Industries Ltd. Investors and Encourages Investors to Contact the Firm (TEVA)
finance.yahoo.com - September 23 at 9:58 AM
finance.yahoo.com logoEQUITY ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 23 at 9:58 AM
finance.yahoo.com logoTeva Pharmaceutical Industries Ltd. : TEVA-US: Dividend Analysis : August 29th, 2017 (record date) : By the numbers : September 21, 2017
finance.yahoo.com - September 23 at 9:58 AM
americanbankingnews.com logoReviewing Teva Pharmaceutical Industries Limited (TEVA) & Its Competitors
www.americanbankingnews.com - September 23 at 8:32 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Downgraded by BidaskClub
www.americanbankingnews.com - September 21 at 10:16 PM
americanbankingnews.com logoSanford C. Bernstein Trims Teva Pharmaceutical Industries Limited (TEVA) Target Price to $20.00
www.americanbankingnews.com - September 21 at 10:54 AM
americanbankingnews.com logoInvestors Purchase High Volume of Teva Pharmaceutical Industries Limited Put Options (TEVA)
www.americanbankingnews.com - September 21 at 2:58 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Expected to Post Earnings of $1.08 Per Share
www.americanbankingnews.com - September 21 at 2:12 AM
nasdaq.com logoTeva Pharma to sell more women's health assets for $1.38 bln
www.nasdaq.com - September 20 at 9:54 AM
businesswire.com logoEagle Pharmaceuticals Licenses Japanese Rights for Bendamustine Hydrochloride Ready-to-dilute and Rapid Infusion Injection Products to SymBio Pharmaceuticals Limited
www.businesswire.com - September 20 at 9:54 AM
finance.yahoo.com logoTeva shares rise on debt covenant amendments
finance.yahoo.com - September 20 at 9:54 AM
finance.yahoo.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Teva Pharmaceutical Industries Ltd. Investors (TEVA)
finance.yahoo.com - September 20 at 9:54 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Teva Pharmaceutical Industries Limited to Contact Brower Piven before the Lead Plaintiff Deadline in Class Action Lawsuit
finance.yahoo.com - September 20 at 9:54 AM
finance.yahoo.com logoEQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 - TEVA
finance.yahoo.com - September 20 at 9:54 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 20 at 9:53 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Given "Hold" Rating at Cantor Fitzgerald
www.americanbankingnews.com - September 19 at 2:32 PM
msn.com logoTeva Pharma to sell more women's health assets for $1.38 billion
www.msn.com - September 19 at 8:29 AM
streetinsider.com logoTeva Pharma (TEVA) to Sell Remaining Global Women’s Health Portfolio for $1.38B
www.streetinsider.com - September 19 at 8:29 AM
News IconUPDATE 1-Teva Pharma to sell more women's health assets for $1.38 bln
www.businessinsider.com - September 19 at 8:29 AM
finance.yahoo.com logo$1.38 billion payday: Teva signs 2 deals for remaining women's health assets
finance.yahoo.com - September 19 at 8:29 AM
finance.yahoo.com logo[$$] Teva Sells Slate of Women’s Health Products in Debt-Reducing Moves
finance.yahoo.com - September 19 at 8:29 AM
finance.yahoo.com logoTeva Completes Amendment to Credit Facilities
finance.yahoo.com - September 19 at 8:28 AM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Nutanix and Teva Pharmaceutical
finance.yahoo.com - September 19 at 8:28 AM
finance.yahoo.com logoTeva shares rise 2% on debt covenant amendments
finance.yahoo.com - September 19 at 8:28 AM
investorplace.com logoA New CEO Only Emboldens the Case for Teva Pharmaceutical Industries Ltd (TEVA) Stock
investorplace.com - September 19 at 7:31 AM
americanbankingnews.com logoRoyal Bank Of Canada Lowers Teva Pharmaceutical Industries Limited (TEVA) Price Target to $15.00
www.americanbankingnews.com - September 18 at 8:16 AM
fool.com logoHalozyme, Inovalon, and Teva Soared This Week: Can They Go Higher? - Motley Fool
www.fool.com - September 18 at 7:11 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Sees Significant Growth in Short Interest
www.americanbankingnews.com - September 18 at 2:48 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited's (TEVA) Hold Rating Reaffirmed at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 17 at 10:22 PM
americanbankingnews.com logoBidaskClub Upgrades Teva Pharmaceutical Industries Limited (TEVA) to Sell
www.americanbankingnews.com - September 17 at 2:42 PM
prnewswire.com logoTEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK ... - PR Newswire (press release)
www.prnewswire.com - September 16 at 9:30 AM
finance.yahoo.com logoBehind TEVA’s Women’s Health Products after 1H17
finance.yahoo.com - September 16 at 9:30 AM
finance.yahoo.com logoBehind TEVA’s Women’s Health Products after 1H17
finance.yahoo.com - September 16 at 9:30 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Teva Pharmaceutical Industries Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 23, 2017 - TEVA
finance.yahoo.com - September 16 at 9:29 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - September 16 at 9:29 AM
reuters.com logoDrug industry on tenterhooks as Maryland price-gouging law nears - Reuters
www.reuters.com - September 15 at 9:50 AM
bloomberg.com logoCVC Nears Deal for Teva's European Women's Health Assets - Bloomberg
www.bloomberg.com - September 15 at 9:50 AM
seekingalpha.com logoTeva's New CEO Is A Blessing
seekingalpha.com - September 15 at 9:50 AM
finance.yahoo.com logoThe Klein Law Firm Reminds Investors of a Class Action Commenced on Behalf of Teva Pharmaceutical Industries Ltd. Shareholders and a Lead Plaintiff Deadline of October 23, 2017
finance.yahoo.com - September 15 at 9:49 AM
finance.yahoo.com logoIs It Too Late To Buy Teva Pharmaceutical Industries Limited (TEVA)?
finance.yahoo.com - September 15 at 9:49 AM
finance.yahoo.com logoINVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Teva Pharmaceutical Industries Limited and Reminds Investors with Losses to Contact the Firm
finance.yahoo.com - September 15 at 9:49 AM
finance.yahoo.com logoWhy New Generic Products Could Boost TEVA’s Revenue Growth
finance.yahoo.com - September 15 at 9:49 AM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Earns "Hold" Rating from Maxim Group
www.americanbankingnews.com - September 14 at 6:38 PM
americanbankingnews.com logoTeva Pharmaceutical Industries Limited (TEVA) Stock Rating Reaffirmed by UBS AG
www.americanbankingnews.com - September 14 at 1:04 PM
reuters.com logoTeva to sell women's health assets to CVC Capital Partners: report - Reuters
www.reuters.com - September 14 at 11:12 AM

Social

Chart

Teva Pharmaceutical Industries Limited (TEVA) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by MarketBeat.com Staff